Tau pathology, composed of the misfolded hyperphosphorylated Tau,1 is involved in more than 20 kinds of neurodegenerative diseases, including Alzheimer’s disease (AD), frontotemporal dementia (FTDP-17), progressive supranuclear palsy, and so on, which collectively referred to as “tauopathies”.2–4 Braak staging is used to describe the stages and location of neurofibrillary tangles in AD,5 and the degree of neurodegeneration and memory impairment are strongly correlated with the amount of abnormal tau aggregates in the brain6. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.